China
北京望石智慧科技有限公司 (StoneWise) is a pioneering tech firm, aiming to revolutionize drug discovery through artificial intelligence. Founded in 2018, this Chinese company integrates diverse fields such as AI, computational chemistry, and pharmacology to expedite drug research and development. Their mission to "expand the boundaries of life with technology" underscores their ambition to ensure every disease has a cure.
Leveraging a team from leading internet firms and renowned pharmaceutical companies, StoneWise offers advanced SAAS software products and milestone-based services to global pharma enterprises and top research institutions. Their platform aids in drug design and project management, targeting drug types ranging from First-in-class to Me-better.
StoneWise's growth caught the attention of major investors, securing a $100.00M Series B investment in April 2021, led by Lightspeed China Partners and others, marking significant investor confidence. With teams in Beijing, Shanghai, and Boston, StoneWise is positioned to lead globally in AI-driven drug research.
